


글로벌 제약사 파이프라인 분석

- Takeda -

2022. 07.


국가신약개발사업단

• 질환별 파이프라인



질환분야	개수	비중
Oncology	20	27%
Immunology	14	19%
Hematology	14	19%
Neuroscience	13	18%
Gastrointestinal	4	5.5%
Infectious	4	5.5%
Metabolic	3	4%
Cardiovascular	1	1%
Renal	1	1%
합계	74개	100%

• 물질별 파이프라인



물질	개수	비중
Small molecules	21	28%
Protein	16	21.5%
Antibody	16	21.5%
Cell Therapy	6	8%
Peptide	3	4%
RNA	3	4%
Vaccine	2	3%
N/A(Not Applicable)	2	3%
ADC	2	3%
Others	2	3%
Virus	1	1%
합계	74개	100%

• 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Cardiovascular	Phase 2		Ceprothin		protein C deficiency	Others	Coagulation Factor V	Coagulation Factor V inhibitor	Mono	-
2	Gastrointestinal	Phase 1	TAK-105			Nausea & vomiting	N/A	N/A	N/A	Mono	-
3	Gastrointestinal	Phase 1	TAK-510			Nausea & vomiting	RNA	N/A	Antisense therapy	Mono	-
4	Gastrointestinal	Phase 2	TAK-951			Nausea & vomiting	RNA	N/A	Antisense therapy	Mono	-
5	Gastrointestinal	Phase 2	TAK-954			Postoperative gastrointestinal tract dysfunction	Small molecules	Serotonin(5-HT4) receptor	Serotonin(5-HT4) receptor agonist	Mono	Theravance Biopharma
6	Hematology	Phase 3	BAX111	Vonvendi	von Willebrand factor	von Willebrand disease adult prophylaxis	Protein	Von Willebrand Factor (VWF)	VWF Replacement	Mono	-
7	Hematology	Phase 3	BAX111	Vonvendi	von Willebrand factor	von Willebrand disease, pediatrics on-demand & surgery	Protein	Von Willebrand Factor (VWF)	(VWF Replacement)	Mono	-
8	Hematology	Phase 1	BAX111	Vonvendi	von Willebrand factor	von Willebrand disease, pediatrics prophylaxis	Protein	Von Willebrand Factor (VWF)	VWF Replacement	Mono	-
9	Hematology	Phase 3	BAX855	Adynovate	antihemophilic factor	Recombinant factor VIII pediatric hemophilia	Protein	Coagulation Factor VIII	Coagulation Factor VIII Replacement	Mono	-
10	Hematology	Phase 3	OBI-1	Obizur	susoctocog alfa	Recombinant antihemophilic factor porcine	Protein	Coagulation Factor VIII	Coagulation Factor VIII Replacement	Mono	-
11	Hematology	Phase 3	TAK-755		apadamtase alfa	Congenital thrombotic thrombocytopenic purpura	Protein	ADAMTS13	ADAMTS13 replacement	Mono	-
12	Hematology	Phase 2	TAK-755		apadamtase alfa	Immune-mediated thrombotic thrombocytopenic purpura	Protein	ADAMTS13	ADAMTS13 replacement	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
13	Hematology	Phase 1	TAK-755			Sickle cell disease	Protein	ADAMTS13	ADAMTS13 replacement	Mono	-
14	Hematology	Phase 3	TAK-880			Primary immunodeficiencies	Antibody	N/A	N/A	Mono	-
15	Hematology	Phase 2	TAK-881			Immunodeficiencies	Antibody	N/A	N/A	Mono	-
16	Hematology	Phase 3		Cuvitru		Primary immunodeficiencies	Protein	N/A	20% SC immunoglobulin	Mono	-
17	Hematology	Phase 3		Hyqvia	hyaluronidase	Primary immunodeficiencies, pediatrics	Antibody	N/A	Enzyme replacement therapy	Mono	-
18	Hematology	Phase 3		Hyqvia	hyaluronidase	Primary immunodeficiencies	Antibody	N/A	Enzyme replacement therapy	Mono	-
19	Hematology	Phase 3			prothromplex	Direct oral anti-coagulation Reversal	Others	Coagulation Factor IX	Coagulation Factor IX Replacement	Mono	-
20	Immunology	Phase 3	Cx601	Alofisel	darvadstrocel	Perianal fistulas in Crohn's disease	Cell Therapy	IDO1	IDO1 inhibitor	Mono	-
21	Immunology	Phase 3	Cx601	Alofisel	darvadstrocel	Perianal fistulas in Crohn's disease, pediatrics	Cell Therapy	IDO1	IDO1 inhibitor	Mono	-
22	Immunology	Phase 3	MLN0002	Entyvio	vedolizumab	Crohn's disease	Antibody	Integrin alpha 4 beta 7	Integrin alpha(4)beta(7) antagonist	Mono	-
23	Immunology	Phase 3	MLN0002	Entyvio	vedolizumab	Graft-versus-host disease	Antibody	Integrin alpha 4 beta 7	Integrin alpha(4)beta(7) antagonist	Mono	-
24	Immunology	Phase 3	MLN0002	Entyvio	vedolizumab	Ulcerative Colitis, pediatrics	Antibody	Integrin alpha 4 beta 7	Integrin alpha(4)beta(7) antagonist	Mono	-
25	Immunology	Phase 3	MLN0002	Entyvio	vedolizumab	Crohn's disease, pediatrics	Antibody	Integrin alpha 4 beta 7	Integrin alpha(4)beta(7) antagonist	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
26	Immunology	Phase 3	SHP643	Takhzyro	Ianadelumab	Hereditary angioedema, pediatrics	Antibody	Plasma kallikrein(LKL B1)	LKLB1 inhibitor	Mono	-
27	Immunology	Phase 3	SHP643	Takhzyro	Ianadelumab	Bradykinin mediated angioedema	Antibody	Plasma kallikrein(LKL B1)	LKLB1 inhibitor	Mono	-
28	Immunology	Phase 2	TAK-018		sibofimloc	Crohn's disease	Small molecules	Bacterial fimbrial adhesin(fimH)	fimH inhibitor	Mono	Vertex Pharmaceuticals
29	Immunology	Phase 1	TAK-018		sibofimloc	Luminal Crohn's disease	Small molecules	Bacterial fimbrial adhesin(fimH)	fimH inhibitor	Mono	Vertex Pharmaceuticals
30	Immunology	Phase 1	TAK-062			Celiac disease	Protein	Alpha Gliadin	Alpha Gliadin inhibitor	Mono	-
31	Immunology	Phase 2	TAK-079		mezagitamab	Myasthenia gravis, Immune thrombocytopenia purpura	Antibody	CD38	CD38 inhibitor	Mono	-
32	Immunology	Phase 1	TAK-079		mezagitamab	Systemic Lupus Erythematosus,	Antibody	CD38	CD38 inhibitor	Mono	-
33	Immunology	Phase 2	TAK-101			Celiac Disease	Protein	N/A	N/A	Mono	Cour Pharmaceutical Development
34	Infectious	Phase 1	TAK-426			Zika vaccine	Vaccine	N/A	N/A	Mono	-
35	Infectious	Phase 3	TAK-438	Vocinti	vonoprazan fumarate	H.pylori	Small molecules	H+/K ATPase Alpha Chain 1	H+/K ATPase Alpha Chain 1 inhibitor	Mono	-
36	Infectious	Phase 3	TAK-620	Livtencity	maribavir	1L Cytomegalovirus(CMV)infection In HSCT	Small molecules	CMV serine/Threonine protein kinase UL97	CMV serine/Threonine protein kinase UL97 inhibitor	Mono	GSK
37	Infectious	Phase 3		Nuvaxovid		COVID-19	Vaccine	SARS-CoV-2S	N/A	Mono	Novavax
38	Metabolic	Phase 3	JR-141	Izcargo	pabinafusp alfa	Hunter syndrome	ADC	Transferrin receptor	Antibody, Enzyme replacement therapy	Mono	JCR Pharmaceuticals

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
39	Metabolic	Phase 1	PTH 1-84	Natpara	parathyroid hormone	Hypoparathyroidism	Protein	Parathyroid hormone(PTH) receptor 1	PTH receptor agonist	Mono	-
40	Metabolic	Phase 2			fazirsiran	Alpha-1 Antitrypsin deficiency - associated liver disease	RNA	Alpha-1 Antitrypsin	Antisense therapy	Mono	Arrowhead Pharmaceuticals
41	Neuroscience	Phase 2	TAK-041			Major Depressive Disorder (anhedonia)	Small molecules	GPR139	GPR139 agonist	Mono	-
42	Neuroscience	Phase 2	TAK-071			Parkinson's Disease	Small molecules	CHRM1	CHRM1 agonist	Mono	-
43	Neuroscience	Phase 1	TAK-341			Parkinson's disease	Antibody	Alpha synuclein	Alpha synuclein inhibitor	Mono	AstraZeneca
44	Neuroscience	Phase 1	TAK-594			Frontotemporal dementia	Protein	Progranulin(PGRN)	PGRN activator	Mono	Denali Therapeutics
45	Neuroscience	Phase 2	TAK-611			Metachromatic Leukodystrophy	Protein	Arylsulfatase A	Enzyme replacement therapy	Mono	-
46	Neuroscience	Phase 2	TAK-653			Major Depressive Disorder (Inadequate resp)	Small molecules	AMPA glutamate receptor	AMPA agonist	Mono	-
47	Neuroscience	Phase 1	TAK-861			narcolepsy type1	Small molecules	OX2R	OX2R agonist	Mono	-
48	Neuroscience	Phase 1	TAK-925			Post-op/anesthesia	Small molecules	OX2R	OX2R agonist	Mono	-
49	Neuroscience	Phase 3	TAK-935		soticlestat	Dravet syndrome	Small molecules	CYP46A1	CYP46A1 inhibitor	Mono	-
50	Neuroscience	Phase 3	TAK-935		soticlestat	Lennox-Gastaut syndrome	Small molecules	CYP46A1	CYP46A1 inhibitor	Mono	-
51	Neuroscience	Phase 2	TAK-994			Narcolepsy type1, narcolepsy type2, idiopathic hypersomnia	Small molecules	OX2R	PX2R agpmost	Mono	-
52	Neuroscience	Phase 3		Hyqvia	hyaluronidase	Chronic Inflammatory demyelinating polyneuropathy	Antibody	N/A	Enzyme replacement therapy	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
53	Neuroscience	Phase 3		Hyqvia	hyaluronidase	Chronic Inflammatory Demyelinating Polyneuropathy, pediatrics	Antibody	N/A	Enzyme replacement therapy	Mono	-
54	Oncology	Phase 3	AP24534	Iclusig	ponatinib hydrochloride	FL Ph+ Acute Lymphocytic Leukemia	Small molecules	BCR-ABL Tyrosine Kinase	BCR-ABL Tyrosine Kinase inhibitor	Mono	-
55	Oncology	Phase 1	AP24534	Iclusig	ponatinib hydrochloride	Ph+ Acute Lymphocytic Leukemia, pediatrics	Small molecules	BCR-ABL Tyrosine Kinase	BCR-ABL Tyrosine Kinase inhibitor	Mono	-
56	Oncology	Phase 3	AP26113	Alunbrig	brigatinib	2L ALK + NSCLC H2H with alectinib in 2L	Small molecules	ALK, EGFR	Dual inhibitor of ALK and EGFR	Mono	-
57	Oncology	Phase 3	MLN9708	Ninlaro	ixazomib citrate	Multiple Myeloma no post-autologous stem cell transplant	Peptide	Proteasome	Proteasome inhibitor	Mono	-
58	Oncology	Phase 3	MLN9708	Ninlaro	ixazomib citrate	Multiple Myeloma maintenance post-autologous stem cell transplant	Peptide	Proteasome	Proteasome inhibitor	Mono	-
59	Oncology	Phase 2	TAK-007			CD19+ hematologic malignancies	Cell Therapy	CD19	Cytotoxic to cells expressing CD19	Mono	-
60	Oncology	Phase 1	TAK-102			Solid tumors	Cell Therapy	GPC3	CAR-T	Mono	-
61	Oncology	Phase 1	TAK-103			Solid tumors	Cell Therapy	N/A	CAR-T	Mono	Noile-Immune Biotech
62	Oncology	Phase 1	TAK-186			EGFR Solid Tumor	Antibody	CD3/EGFR	Bispecific antibody (CD3/EGFR antagonist)	Mono	-
63	Oncology	Phase 3	TAK-385		relugolix	Prostate cancer	Peptide	GnRH receptor	GnRH receptor antagonist	Mono	-
64	Oncology	Phase 1	TAK-500			Solid tumors	ADC	TMEM173	TMEM173 agonist	Mono	-
65	Oncology	Phase 1	TAK-573		modakafuspalfa	Solid tumors	Protein	CD38	Cytotoxic to cells expressing CD38	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
66	Oncology	Phase 1	TAK-573		modakafusp a lfa	Relapsed/Refractory Multiple Myeloma	Protein	CD38	Cytotoxic to cells expressing CD38	Mono	-
67	Oncology	Phase 1	TAK-605			Multiple cancers	Virus	CTLA-4	Oncolytic virus	Mono	Turnstone Biologics
68	Oncology	Phase 1	TAK-676			Solid tumors	Small molecules	TMEM173	TMEM173 agonist	Mono	-
69	Oncology	Phase 3	TAK-788	Exkivity	mobocertinib	1L NSCLC	Small molecules	EGFR, EGFR2	EGFR/EGFR2 inhibitor	Mono	-
70	Oncology	Phase 1	TAK-940			CD19+ hematologic malignancies	Cell Therapy	CD19	CAR-T	Mono	-
71	Oncology	Phase 2	TAK-981		subasumstat	Multiple cancers	Small molecules	Small ubiquitin-like modifier	sumoylation inhibitor	Mono	-
72	Oncology	Phase 3	XL184	Cabometyx+atezolizumab	cabozantinib+atezolizumab	Metastatic castrate-resistant prostate cancer	Small molecules	VEGF	VEGF inhibitor	Combination	Exelixis
73	Oncology	Phase 3	XL184	Cabometyx+atezolizumab	cabozantinib+atezolizumab	2L metastatic NSCLC	Small molecules	VEGF	VEGF inhibitor	Combination	Exelixis
74	Renal	Phase 1	TAK-039			Hepatic encephalopathy	N/A	N/A	N/A	Mono	-

자료: Takeda 홈페이지, BioCentury, GlobalData